Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kymera Therapeutics, Inc.

45.76
+0.62001.37%
Post-market: 44.99-0.7470-1.63%18:58 EDT
Volume:573.99K
Turnover:25.93M
Market Cap:3.21B
PE:-14.70
High:45.99
Open:45.04
Low:44.11
Close:45.14
Loading ...

Kymera Therapeutics Inc : Stifel Resumes Coverage With Buy Rating; Target Price $55

THOMSON REUTERS
·
20 May

Kymera Therapeutics presents preclinical data for KT-621

TIPRANKS
·
20 May

Kymera Therapeutics Is Maintained at Buy by UBS

Dow Jones
·
13 May

UBS Adjusts Price Target on Kymera Therapeutics to $70 From $72, Maintains Buy Rating

MT Newswires Live
·
13 May

Kymera Therapeutics Is Maintained at Neutral by B of A Securities

Dow Jones
·
12 May

Kymera Therapeutics price target lowered to $44 from $47 at BofA

TIPRANKS
·
12 May

Kymera Therapeutics: Promising Pipeline and Strategic Decisions Justify Buy Rating

TIPRANKS
·
12 May

Stock Track | Kymera Therapeutics Soars 9.33% on Strong Q1 Earnings and New Drug Program Announcement

Stock Track
·
09 May

Kymera Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
09 May

Kymera Therapeutics Q1 Loss Widens, Collaboration Revenue Rises

MT Newswires Live
·
09 May

Kymera Therapeutics reports Q1 EPS (82c), consensus (91c)

TIPRANKS
·
09 May

Kymera Therapeutics expects cash to provide cash runway into 1H of 2028

TIPRANKS
·
09 May

Earnings Flash (KYMR) Kymera Posts Q1 Collaboration Revenue $22.1M, vs. FactSet Est of $10.7M

MT Newswires Live
·
09 May

Earnings Flash (KYMR) Kymera Therapeutics Posts Q1 Loss $0.82 a Share, vs. FactSet Est of $0.88 Loss

MT Newswires Live
·
09 May

Kymera Therapeutics: New First-in-Class, Oral Irf5 Degrader Program With Potential to Address Multiple Immuno-Inflammatory Diseases

THOMSON REUTERS
·
09 May

Kymera Therapeutics: KT-579 Ind-Enabling Studies Ongoing, Phase 1 Testing to Begin Early 2026

THOMSON REUTERS
·
09 May

Kymera Therapeutics Q1 EPS $(0.82) Beats $(0.92) Estimate, Collaboration Revenue $22.10M Beat $10.15M Estimate

Benzinga
·
09 May

Kymera Therapeutics Inc: Strategic Decision Made Not to Advance KT-295 (Tyk2) Into Further Clinical Development

THOMSON REUTERS
·
09 May

Kymera Therapeutics Inc: Cash as of March 31, NOW Providing Extended Runway Into First Half of 2028

THOMSON REUTERS
·
09 May

Why Kymera Therapeutics Stock Crushed it This Week

Motley Fool
·
26 Apr